A Study of Toripalimab+ Pemetrexed Plus Carboplatin in Patients With EGFR-mutation Positive and T790M Negative After Progression on EGFR-TKI Treatment

Phase 2 Completed 40 enrolled Shanghai Junshi Bioscience Co., Ltd.

NaSingle-groupOpen-labelTreatment

Summary

JS001 combined with pemetrexed plus carboplatin for treatment of recurrent or advanced non-small-cell lung cancer with EGFR-mutation positive and T790M negative after progression on EGFR-TKI treatment：a multi-center, single arm phase II study

Timeline

Start: 2018-04-09
Primary completion: 2022-08-12
Completion: 2022-08-12

Publications

Li LC, Chen XW, Fang L, Jian CL, Yu YX, Liao XY, Sun JG. YAP1 as a Novel Negative Biomarker of Immune Checkpoint Inhibitors for EGFR-Mutant Non-Small-Cell Lung Cancer. Can Respir J. 2023 Jun 21;2023:4689004. doi: 10.1155/2023/4689004. eCollection 2023.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Carboplatin	Small molecule	—	—
Subject	Pemetrexed	Small molecule	—	—
Subject	Toripalimab	Monoclonal antibody	240 mg	—
Subject	Toripalimab	Monoclonal antibody	360 mg	—

A Study of Toripalimab+ Pemetrexed Plus Carboplatin in Patients With EGFR-mutation Positive and T790M Negative After Progression on EGFR-TKI Treatment

Summary

Timeline

Publications

Drugs

Indications